CN100337645C - Medicine composition for treating acute pharyngitis and its prepn - Google Patents
Medicine composition for treating acute pharyngitis and its prepn Download PDFInfo
- Publication number
- CN100337645C CN100337645C CNB021126356A CN02112635A CN100337645C CN 100337645 C CN100337645 C CN 100337645C CN B021126356 A CNB021126356 A CN B021126356A CN 02112635 A CN02112635 A CN 02112635A CN 100337645 C CN100337645 C CN 100337645C
- Authority
- CN
- China
- Prior art keywords
- group
- radix
- hours
- beta
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a compound Chinese medicine preparation, particularly to a medicinal composition for treating acute pharyngitis and a method for preparing the medicinal composition. The medicinal composition is mainly composed of nine traditional Chinese medicines of radix glycyrrhiza, platycodon roots, blackberrylily rhizomes, great burdock achene, herba menthae, cicada slough, figwort roots, red peony roots and fineleaf schizonepeta herbs, and the medicinal composition can contain an excipient which can be accepted in a pharmaceutical way so as to be made into granules, capsules or tablets. The medicinal composition has the obvious functions of antisepsis, inflammation resistance, analgesia and phlegm elimination, and the medicinal composition can effectively treat acute pharyngitis, and prevent the protracted course of acute pharyngitis or reduce the repeated attacks of acute pharyngitis without an adverse reaction.
Description
The invention belongs to composite Chinese medicine preparation, be meant a kind of pharmaceutical composition for the treatment of acute pharyngitis and preparation method thereof especially.
Acute pharyngitis is a kind of commonly encountered diseases, frequently-occurring disease, often is the part of upper respiratory tract infection.Show as isthmus faucium position burst congestion and swelling pain clinically, particularly evident when swallowing saliva.Doctor trained in Western medicine is used antibiotic therapy always, easily produces untoward reaction such as drug resistance and gastrointestinal upset; The traditional Chinese medical science is used the Chinese patent drugs for treatment acute pharyngitis that some heat-clearing and toxic substances removing, YIN nourishing wet one's whistle always.But should disease such as malpractice, through regular meeting's protracted course of disease or show effect into chronic pharyngitis repeatedly.
The object of the present invention is to provide a kind of acute pharyngitis to be had significant therapeutic effect, can prevent or reduce acute pharyngitis protracted course of disease or outbreak repeatedly, and the pharmaceutical composition that has no adverse reaction and preparation method thereof.
The objective of the invention is to reach by following measure:
Drug weight part proportioning of the present invention is:
Radix Glycyrrhizae 700g Radix Platycodonis 250g Rhizoma Belamcandae 280g
Fructus Arctii 200g Herba Menthae 200g Periostracum Cicadae 320g
Radix Scrophulariae 500g Radix Paeoniae Rubra 600g Herba Schizonepetae 330g
Preparation method of the present invention is:
Radix Glycyrrhizae, Radix Platycodonis, Fructus Arctii, Rhizoma Belamcandae, Radix Scrophulariae, Radix Paeoniae Rubra, Periostracum Cicadae are pulverized, decoct with water more than twice, be no less than 1 hour at every turn, decocting liquid merges.Herba Schizonepetae, Herba Menthae are used steam distillation, isolate volatile oil, and remaining distillate and decocting liquid merge filtration.Filtrate decompression is concentrated into the extractum liquid that relative density is 1.15-1.25 (80-90 ℃ heat survey), puts and is chilled to room temperature, adds ethanol and is adjusted to and contains alcohol amount 40-70% (w/w), and the limit edged stirs, and leaves standstill more than 12 hours.Get supernatant, being evaporated to relative density is the thick extractum of 1.35-1.45 (80-90 ℃ of heat is surveyed).With separate Herba Schizonepetae-Herba Menthae Haplocalycis volatile oil be added dropwise to saturated beta-schardinger dextrin-aqueous solution while stirring, add the back and continue to stir more than 2 hours, place more than 12 hours, filter, beta-cyclo dextrin included compound.Thick extractum is mixed with beta-cyclo dextrin included compound, get pharmaceutical composition of the present invention.
Pharmaceutical composition of the present invention can contain pharmaceutically acceptable excipient, as Icing Sugar, dextrin, starch, makes granule or capsule or tablet or oral liquid.
The present invention is further elaborated with the biological activity test example by the following examples:
Embodiment 1
Pharmaceutical composition of the present invention is made by following proportion raw material medical material:
Radix Glycyrrhizae 700g Radix Platycodonis 250g Rhizoma Belamcandae 280g
Fructus Arctii 200g Herba Menthae 200g Periostracum Cicadae 320g
Radix Scrophulariae 500g Radix Paeoniae Rubra 600g Herba Schizonepetae 330g
Preparation method:
Radix Glycyrrhizae, Radix Platycodonis, Fructus Arctii, Rhizoma Belamcandae, Radix Scrophulariae, Radix Paeoniae Rubra, Periostracum Cicadae are pulverized, decoct with water twice, each 90 minutes, decocting liquid merged.Herba Schizonepetae, Herba Menthae are used steam distillation, isolate volatile oil, and remaining distillate and decocting liquid merge filtration.Filtrate decompression is concentrated into relative density the be 1.15 extractum liquid of (80 ℃ of heat are surveyed), puts and is chilled to room temperature, adds ethanol and is adjusted to and contains alcohol amount 60% (w/w), and the limit edged stirs, and leaves standstill 24 hours.Get supernatant, being evaporated to relative density is the thick extractum of 1.36 (80 ℃ of heat are surveyed).With separate Herba Schizonepetae-Herba Menthae Haplocalycis volatile oil be added dropwise to saturated beta-schardinger dextrin-aqueous solution while stirring, add the back and continue to stir 2 hours, places 16 hours after-filtration, drying, beta-cyclo dextrin included compound.Thick extractum is mixed with beta-cyclo dextrin included compound, get pharmaceutical composition 720g of the present invention.
Pharmaceutical composition 720g
Icing Sugar 450g
Dextrin 200g
According to the conventional preparation technology of granule, Icing Sugar and dextrin are added pharmaceutical composition, mix homogeneously is made granule, 60 ℃ of dryings, packing is promptly.
The biological activity test example
Example 1: bacteriostatic test in the body
Animal: 100 of Kunming mouses
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.6g, 1.7g, 5.0g extract powder respectively)
Matched group: SHUANGHUANGLIAN KOUFUYE 25ml/Kg
Test method: 10 every group of mices, administration every day 1 time continuous 5 days, is infected staphylococcus aureus, the death toll of observing mice in 24 hours in the 30min mouse peritoneum after the last administration.The results are shown in following table:
| Group | Dosage (g/kg) | Number of animals (only) | Death toll (only) | Mortality rate (%) |
| The heavy dose of group of dosage group SHUANGHUANLIAN group in the normal saline group small dose group | - 0.6 1.7 5.0 25ml/Kg | 20 20 20 20 20 | 18 19 14 9 11 | 90 95 70 45 ** 55 ** |
Compare with the normal saline group,
*P＜0.05.
The result shows that the heavy dose of group of pharmaceutical composition of the present invention can reduce mortality rate to the infection of staphylococcus aureus mice, has the certain protection effect.
Example 2: antiinflammatory test
(1) to the swollen outgrowth influence of rat granuloma
Animal: 50 of male SD rats
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.4g, 1.3g, 3.8g extract powder respectively)
Matched group: aspirin 0.1g/Kg
Test method: 10 every group of rats, cotton balls is implanted in the anesthesia back, and postoperative is gastric infusion respectively, administration every day 1 time, continuous 7 days.Put to death rat on the 8th day, calculate the granuloma net weight, the results are shown in following table:
| Group | Dosage (g/Kg) | Number of animals (only) | Granuloma dry weight (mg/100g) | Suppression ratio (%) |
| The heavy dose of group of dosage group aspirin group in the normal saline group small dose group | - 0.4 1.3 3.8 0.1 | 9 10 9 10 9 | 49.1±13.3 36.8±10.3 * 33.4±13.2 * 33.0±10.9 * 30.7±9.4 ** | 25.05 31.98 32.79 37.47 |
Compare with matched group,
*P＜0.05,
*P＜0.01.
Annotate: 3 rats are destroyed because of operation suture thread, and the cotton balls that causes implanting is lost, and can't calculate, and therefore exclude result of the test.
The result shows, compare with the normal saline matched group, each dosage group of pharmaceutical composition of the present invention all can significantly suppress by the rat chronic granulation tissue hyperplasia due to the implantation cotton balls, and suppression ratio is respectively 25.05%, 31.98%, 32.79%, illustrates that it has certain inhibitory action to chronic inflammatory disease.
(2) influence of xylol induced mice auricle inflammation
Animal: 50 of Kunming mouses
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.6g, 1.7g, 5.0g extract powder respectively)
Matched group: aspirin 0.1g/Kg
Test method: 10 every group of mices, administration every day 1 time continuous 3 days, after the last administration 1 hour, is smeared to mouse ear with dimethylbenzene.Put to death mice after 1 hour, calculate the auricle edema value, the results are shown in following table:
| Group | Dosage (g/Kg) | Auricle edema value (g) | Auricle edema rate (%) | Suppression ratio (%) |
| The heavy dose of group of dosage group aspirin group in the normal saline group small dose group | - 0.6 1.7 5.0 0.1 | 10.6±2.2 8.4±2.5 8.2±2.1 7.9±2.0 7.3±2.1 | 166.4±43.8 121.8±37.0 * 124.4±43.5 * 117.5±38.9 * 109.9±37.6 ** | 26.8 25.2 29.4 34.0 |
Compare with matched group,
*P＜0.05,
*P＜7.30.01.
The result shows, compares with the normal saline matched group, and each dosage group of pharmaceutical composition of the present invention all can significantly suppress the Mice Auricle inflammation due to the dimethylbenzene, and suppression ratio is respectively 26.8%, 25.2%, 29.4%.
(3) on Carrageenan causes the influence of rat paw edema
Animal: 50 of male SD rats
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.4g, 1.3g, 3.8g extract powder respectively)
Matched group: aspirin 0.1g/Kg
Test method: 10 every group of mices, gastric infusion respectively, after the administration 1 hour, in the right back sufficient sole of the foot injection carrageenin of rat, cause scorching back 1,2,4,6 hour, measure sufficient sole of the foot volume respectively, calculate swelling value, swelling rate, the results are shown in following table:
| Group | Dosage (g/Kg) | Swelling value (ml) | |||
| 1h | 2h | 4h | 6h | ||
| The heavy dose of group of dosage group aspirin group in the normal saline group small dose group | - 0.4 1.3 3.8 0.1 | 0.41±0.15 0.35±0.13 0.22±0.13 ** 0.24±0.13 * 0.25±0.16 | 0.73±0.13 0.50±0.9 ** 0.49±0.16 ** 0.47±0.16 ** 0.41±0.15 ** | 0.55±0.15 0.42±0.12 0.34±0.15 ** 0.33±0.16 ** 0.28±0.17 ** | 0.37±0.15 0.31±0.12 0.26±0.15 0.30±0.15 0.24±0.13 |
Compare with matched group,
*P＜0.05,
*P＜0.01.
| Group | Dosage (g/Kg) | Swelling rate (%) | |||
| 1h | 2h | 4h | 6h | ||
| The heavy dose of group of dosage group aspirin group in the normal saline group small dose group | - 2.5 5 10 0.1 | 44.0±20.1 37.2±16.9 26.0±17.6 * 26.5±16.2 * 25.5±16.7 * | 76.4±19.8 53.5±25.3 * 55.6±23.3 * 52.2±22.7 * 42.9±18.3 * | 58.2±21.8 44.7±18.2 40.1±21.5 37.3±21.6 * 30.6±20.9 * | 39.7±19.8 33.7±17.7 29.8±19.3 34.3±20.3 26.3±19.7 |
Compare with matched group,
*P＜0.05,
*P＜0.01.
The result shows, compares with the normal saline group, and each dosage group of pharmaceutical composition of the present invention all can obviously suppress the rat paw edema due to the carrageenin, onset in 1 hour after the general administration, and effect lasted till 4 hours.
(4) to the influence of mouse peritoneal capillary permeability
Animal: 50 of Kunming mouses
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.6g, 1.7g, 5.0g extract powder respectively)
Matched group: aspirin 0.1g/Kg
Test method: 10 every group of mices, administration every day 1 time, continuous 3 days, after the last administration 1 hour, behind the mouse tail vein injection azovan blue normal saline, lumbar injection acetic acid normal saline, put to death mice after 30 minutes, measure the optical density value of abdominal cavity cleaning mixture, the results are shown in following table:
| Group | Dosage (g/Kg) | Optical density value (OD) |
| The heavy dose of group of dosage group aspirin group in the normal saline group small dose group | - 0.6 1.7 5.0 0.1 | 0.370±0.137 0.264±0.162 0.190±0.106 ** 0.196±0.112 ** 0.211±0.111 * |
Compare with the normal saline group,
*P＜0.05,
*P＜0.01.
The result shows, with the normal saline group relatively, the mouse peritoneal capillary permeability due to the big or middle dosage group of the pharmaceutical composition of the present invention Dichlorodiphenyl Acetate increases obvious inhibitory action.
Example 3: analgesic test
The influence of Dichlorodiphenyl Acetate induced mice writhing response
Animal: 50 of Kunming mouses
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.6g, 1.7g, 5.0g extract powder respectively)
Matched group: aspirin 0.2g/Kg
Test method: 10 every group of mices, after the administration 1 hour, mouse peritoneal injection acetum, that observes each treated animal in 15 minutes turns round the body number of times, the results are shown in following table:
| Group | Dosage (g/Kg) | Turn round the body number of times | Suppression ratio (%) |
| The heavy dose of group of dosage group aspirin group in the normal saline group small dose group | - 0.6 1.7 5.0 0.2 | 47.5±12.4 36.6±10.1 * 34.0±9.3 * 32.6±10.5 ** 31.5±12.2 ** | 22.9 28.4 31.4 33.7 |
Compare with matched group,
*P＜0.05,
*P＜0.01.
The result shows, with the normal saline matched group relatively, the mouse writhing reaction due to each dosage group Dichlorodiphenyl Acetate of pharmaceutical composition of the present invention has obvious inhibitory action, suppression ratio is respectively 22.9%, 28.4%, 31.4%, illustrates that it has certain analgesic activity.
Example 4: expectorant test
Influence to the phenol red discharge rate of mice trachea
Animal: 50 of Kunming mouses
Medicine-feeding way: irritate stomach
The administration group: little, in, heavy dose of (being equivalent to 0.6g, 1.7g, 5.0g extract powder respectively)
Matched group: ammonium chloride 1.0g/Kg
Test method: 10 every group of mices, after the administration 1 hour, mouse peritoneal injection phenol red solution was put to death mice after 30 minutes, measured the optical density value of trachea cleaning mixture, the results are shown in following table:
| Group | Dosage (g/Kg) | Phenol red output (μ g/ml) | Rate of increase (%) |
| The heavy dose of group of dosage group sodium chloride group in the normal saline group small dose group | - 0.6 1.7 5.0 1.0 | 0.48±0.29 0.78±0.32 * 0.81±0.37 * 0.88±0.32 ** 1.04±0.27 ** | 62.5 68.8 83.3 116.7 |
Compare with the normal saline group,
*P＜0.05,
*P＜0.01.
The result shows, compares with the normal saline matched group, and each dosage group of pharmaceutical composition of the present invention all can obviously promote the phenol red discharge of mice trachea, illustrates that it has certain phlegm-dispelling functions.
From the biological activity test result as can be seen, that pharmaceutical composition of the present invention has is antibiotic significantly, antiinflammatory, phlegm-dispelling functions, thus acute pharyngitis is had significant therapeutic effect, and can prevent or reduce acute pharyngitis protracted course of disease or outbreak repeatedly, and have no adverse reaction.
Claims (3)
1, a kind of pharmaceutical composition for the treatment of acute pharyngitis is characterized in that: be to be made by following materials of weight proportions medical material:
Radix Glycyrrhizae 700g Radix Platycodonis 250g Rhizoma Belamcandae 280g
Fructus Arctii 200g Herba Menthae 200g Periostracum Cicadae 320g
Radix Scrophulariae 500g Radix Paeoniae Rubra 600g Herba Schizonepetae 330g
Preparation method is: Radix Glycyrrhizae, Radix Platycodonis, Fructus Arctii, Rhizoma Belamcandae, Radix Scrophulariae, Radix Paeoniae Rubra, Periostracum Cicadae are pulverized, decoct with water more than twice, be no less than 1 hour at every turn, decocting liquid merges; Herba Schizonepetae, Herba Menthae are used steam distillation, isolate volatile oil, and remaining distillate and decocting liquid merge filtration; Filtrate decompression is concentrated into the extractum liquid that 80-90 ℃ of heat is surveyed relative density 1.15-1.25, puts and is chilled to room temperature, adds ethanol and is adjusted to and contains alcohol amount 40-70% (W/W), and the limit edged stirs, and leaves standstill more than 15 hours; Get supernatant, being evaporated to 80-90 ℃ of heat survey relative density is the thick extractum of 135-1.45; With separate Herba Schizonepetae-Herba Menthae Haplocalycis volatile oil be added dropwise to saturated beta-schardinger dextrin-aqueous solution while stirring, add the back and continue to stir more than 2 hours, place more than 12 hours, filter, beta-cyclo dextrin included compound, thick extractum is mixed with beta-cyclo dextrin included compound.
2, pharmaceutical composition according to claim 1 is characterized in that, also contains pharmaceutically acceptable excipient, makes granule, capsule, tablet or oral liquid.
3, the described preparation of drug combination method of claim 1 is characterized in that: Radix Glycyrrhizae, Radix Platycodonis, Fructus Arctii, Rhizoma Belamcandae, Radix Scrophulariae, Radix Paeoniae Rubra, Periostracum Cicadae are pulverized, decoct with water more than twice, be no less than 1 hour at every turn, decocting liquid merges; Herba Schizonepetae, Herba Menthae are used steam distillation, isolate volatile oil, and remaining distillate and decocting liquid merge filtration; Filtrate decompression is concentrated into the extractum liquid that 80-90 ℃ of heat is surveyed relative density 1.15-1.25, puts and is chilled to room temperature, adds ethanol and is adjusted to and contains alcohol amount 40-70% (W/W), and the limit edged stirs, and leaves standstill more than 15 hours; Get supernatant, being evaporated to 80-90 ℃ of heat survey relative density is the thick extractum of 1.35-1.45; With separate Herba Schizonepetae-Herba Menthae Haplocalycis volatile oil be added dropwise to saturated beta-schardinger dextrin-aqueous solution while stirring, add the back and continue to stir more than 2 hours, place more than 12 hours, filter, beta-cyclo dextrin included compound, thick extractum is mixed with beta-cyclo dextrin included compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021126356A CN100337645C (en) | 2002-02-05 | 2002-02-05 | Medicine composition for treating acute pharyngitis and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021126356A CN100337645C (en) | 2002-02-05 | 2002-02-05 | Medicine composition for treating acute pharyngitis and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1436555A CN1436555A (en) | 2003-08-20 |
| CN100337645C true CN100337645C (en) | 2007-09-19 |
Family
ID=27628344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021126356A Expired - Lifetime CN100337645C (en) | 2002-02-05 | 2002-02-05 | Medicine composition for treating acute pharyngitis and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100337645C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100337648C (en) * | 2005-06-22 | 2007-09-19 | 贵州正鑫药业有限公司 | Chinese medicine preparation for treating acute pharyngitis and acute tonsillitis and its preparation method |
| CN102755461A (en) * | 2012-06-14 | 2012-10-31 | 荣坤 | Traditional Chinese medicinal fruit and vegetable compound oral solution for treating acute pharyngitis |
| CN102772666A (en) * | 2012-06-14 | 2012-11-14 | 何梅 | Traditional Chinese medicine composite oral liquid for treating pharyngitis |
| CN102973771B (en) * | 2012-11-22 | 2014-06-25 | 项孝泓 | Chinese traditional medicine composite for curing chronic pharyngitis |
| CN105663433A (en) * | 2016-02-29 | 2016-06-15 | 戴礼礼 | Pharmaceutical preparation for treating acute pharyngitis and preparation method and use thereof |
| CN107050109A (en) * | 2016-12-22 | 2017-08-18 | 深圳海王医药科技研究院有限公司 | It is a kind of while extracting the preparation method that sterilization dissipates Chinese medical extract and volatile oil |
| CN111067999A (en) * | 2019-12-14 | 2020-04-28 | 袁图春 | Chinese patent medicine for treating acute pharyngitis and preparation method thereof |
| CN111888413B (en) * | 2020-09-18 | 2022-07-12 | 天津中医药大学 | Pharmaceutical composition for autumn respiratory diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238969A (en) * | 1998-06-12 | 1999-12-22 | 许世平 | 'Qingyan' pill for treating pharynigits |
-
2002
- 2002-02-05 CN CNB021126356A patent/CN100337645C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238969A (en) * | 1998-06-12 | 1999-12-22 | 许世平 | 'Qingyan' pill for treating pharynigits |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1436555A (en) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836725A (en) | Traditional Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN105362340B (en) | A kind of pharmaceutical composition for treating leukaemia and preparation method thereof | |
| CN100337645C (en) | Medicine composition for treating acute pharyngitis and its prepn | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN1943768A (en) | A Chinese traditional medicine for treatment of hemorrhoid, anal fistula and anal fissure and their preparation methods | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN1709288A (en) | Medicinal composition, and its preparing method and use | |
| CN1857684A (en) | Compound Chinese medicine preparation for removing toxic matter, dispersing blood clots and strengthing body's resistance and its preparaing process | |
| CN100363043C (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1299757C (en) | Chinese medicinal composition for treating scapulohumeral periarthritis and preparing method thereof | |
| CN104147257A (en) | Medicine for treating balanitis | |
| CN1259939C (en) | Traditional Chinese medicine formulation for oral disease and its preparation method | |
| CN1615923A (en) | Medicinal composition and its preparing method and use | |
| CN1231242C (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN1927282A (en) | Preparation for treating arthritis and preparation method thereof | |
| CN104095940A (en) | Traditional Chinese medicine composition for treating gout | |
| CN1593564A (en) | Medicine for treating cold and its preparing process | |
| CN114949084B (en) | A Chinese medicinal composition for treating prostatosis, and its preparation method | |
| CN1258373C (en) | Medicine for treating lumbosacral pain and its preparing method | |
| CN1466981A (en) | Compound rhizome of Cyrtomium aspirin tablet | |
| CN107510716B (en) | Pharmaceutical composition for treating irritable bowel syndrome and preparation method and application thereof | |
| CN1308017C (en) | Medicine composition for treating eliminateion, dysentery and eruptive disease | |
| CN1440777A (en) | Acne treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHENGZHOU ZHUOFENG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING KAIYOU TECH AND TRADE CO., LTD. Effective date: 20100108 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100108 Address after: East of 107 National Road, North City area (new town), Xinzheng, Henan Patentee after: ZHENGZHOU CHEUK-FUNG PHARMACEUTICAL CO., LTD. Address before: Nanjing City, Jiangsu province Longpan Road No. 69 Beiyuan Building Room 408 Patentee before: Nanjing Kaoyou Science &. Trade Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20070919 |
|
| CX01 | Expiry of patent term |